|Articles|September 5, 2019

Advarra Announces Intent to Acquire Forte

Advarra has announced its the intent to acquire Forte and is expecting to close later in this month.

For details, click here.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!

Related Content

Novo Nordisk Submits Higher-Dose Wegovy Injectable for FDA Approval with Priority Voucher

ByNicholas Jacobus

November 28th 2025

FDA Approves Imfinzi Plus FLOT for Early and Locally Advanced Gastric and GEJ Cancers

ByAndy Studna, Senior Editor

November 26th 2025

The CRA Role’s Co-evolution With Clinical Trial Technology

ByHelen Yeardley

November 26th 2025

ACT Brief: AI in Clinical Research, FDA Gene Therapy Approval, and High-Performing Hospital Partnerships

ByAndy Studna, Senior Editor

November 26th 2025

© Rochu_2008 - © Rochu_2008 - stock.adobe.com

FDA Clears Itvisma as First Gene Therapy for Adolescents and Adults With SMA

ByAndy Studna, Senior Editor

November 25th 2025

Advarra Announces Intent to Acquire Forte

Newsletter

Related Content

Novo Nordisk Submits Higher-Dose Wegovy Injectable for FDA Approval with Priority Voucher

FDA Approves Imfinzi Plus FLOT for Early and Locally Advanced Gastric and GEJ Cancers

The CRA Role’s Co-evolution With Clinical Trial Technology

ACT Brief: AI in Clinical Research, FDA Gene Therapy Approval, and High-Performing Hospital Partnerships

FDA Clears Itvisma as First Gene Therapy for Adolescents and Adults With SMA

Trending on Applied Clinical Trials Online

Is Artificial Intelligence Coming for Clinical Research?

FDA Approves Imfinzi Plus FLOT for Early and Locally Advanced Gastric and GEJ Cancers

Novo Nordisk Submits Higher-Dose Wegovy Injectable for FDA Approval with Priority Voucher

The CRA Role’s Co-evolution With Clinical Trial Technology

FDA Clears Itvisma as First Gene Therapy for Adolescents and Adults With SMA